BET (ACTIV-5)

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Hospitalized, Ordinal 5, 6 or 7

Diagnosis Required

Hospitalized with COVID

Diseases Being Studied

SARS-CoV-2
Location: San Antonio, TX

Sponsor: NIH-NIAID

Coordinating Center/CRO: DLH Corp

Primary Objective: To evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.

Study drugs: 5B-Lenzilumab/Remdesivir vs Placebo/Remdesivir

Study Progress: Enrollment in BET B closed 1/9/22 with ~400 enrolled. BET C continues, but we are not participating

Our Final enrollment: 13, 1 death on study; 12 completed D60

Meet Your Clinical Research Team

Contact us

Principal Investigator: Local PI: Jan Patterson, M.D., M.S., Philip Ponce, M.D., and Barbara Taylor, M.D., M.S.

For questions on the study, please contact Dr. Jan Patterson